<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Croat Med J</journal-id><journal-id journal-id-type="iso-abbrev">Croat Med J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Croatian Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0353-9504</issn><issn pub-type="epub">1332-8166</issn><publisher><publisher-name>Croatian Medical Schools</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40343436</article-id><article-id pub-id-type="pmc">PMC12093124</article-id><article-id pub-id-type="publisher-id">CroatMedJ_66_0135</article-id><article-id pub-id-type="doi">10.3325/cmj.2025.66.135</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jurin</surname><given-names>Ivana</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Had&#x0017e;ibegovi&#x00107;</surname><given-names>Irzal</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jurin</surname><given-names>Hrvoje</given-names></name><xref rid="aff4" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rudan</surname><given-names>Diana</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pavlovi&#x00107;</surname><given-names>Nikola</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Radi&#x00107;</surname><given-names>Marija</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Manola</surname><given-names>&#x00160;ime</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Trkulja</surname><given-names>Vladimir</given-names></name><xref rid="aff7" ref-type="aff">
<sup>6</sup>
</xref></contrib><aff id="aff1">Jurin et al: Dapagliflozin and empagliflozin for heart failure</aff><aff id="aff2"><label>1</label>Department of Cardiovascular Diseases, University Hospital Dubrava, Zagreb, Croatia</aff><aff id="aff3"><label>2</label>Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University, Osijek, Croatia</aff><aff id="aff4"><label>3</label>Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia</aff><aff id="aff5"><label>4</label>University North, Koprivnica, Croatia</aff><aff id="aff6"><label>5</label>Zagreb University School of Medicine, Zagreb, Croatia</aff><aff id="aff7"><label>6</label>Department of Pharmacology and Clinical Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to:&#x02028;Vladimir Trkulja&#x02028;Department of Pharmacology and Clinical Pharmacology&#x02028;Zagreb University School of Medicine&#x02028;&#x00160;alata 11&#x02028;10000 Zagreb, Croatia&#x02028;<italic><email xlink:href="vladimir.trkulja@mef.hr">vladimir.trkulja@mef.hr</email></italic></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>66</volume><issue>2</issue><fpage>135</fpage><lpage>152</lpage><permissions><copyright-statement>Copyright &#x000a9; 2025 by the Croatian Medical Journal. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Aim</title><p>To assess the relative efficacy of dapagliflozin and empagliflozin in routinely treated chronic heart failure (CHF) patients.</p></sec><sec><title>Methods</title><p>Data from a registry of prevalent and incident CHF patients were used to set up cohorts (new-user design) of patients started on dapagliflozin or empagliflozin in addition to other guideline-directed therapy. Cohorts were mutually balanced on a range of characteristics, and were assessed for the incidence of a composite of all-cause death/major adverse cardiac events (primary outcome) over the initial 6 months of treatment, and for New York Heart Association (NYHA) functional class at 6 months (secondary outcome). Frequentist and Bayes estimates were generated for the dapagliflozin vs empagliflozin comparison.</p></sec><sec><title>Results</title><p>In both prevalent (dapagliflozin n&#x02009;=&#x02009;393, empagliflozin n&#x02009;=&#x02009;328) and incident (dapagliflozin n&#x02009;=&#x02009;124, empagliflozin n&#x02009;=&#x02009;116) patients, those prescribed dapagliflozin had somewhat higher incidence of the primary outcome, but the confidence intervals were wide (RR&#x02009;=&#x02009;1.385, 95%CI 0.882-2.173 [prevalent], RR&#x02009;=&#x02009;2.192, 95%CI 0.765-6.282 [incident]), and were more likely to present with a worse NYHA class at 6 months (OR&#x02009;=&#x02009;1.552, 95%CI 1.142-2.108 [prevalent], OR&#x02009;=&#x02009;1.503, 95%CI 0.844-2.676 [incident]). In the pooled data, primary events (n&#x02009;=&#x02009;102) were more common in dapagliflozin-prescribed patients (frequentist estimate RR&#x02009;=&#x02009;1.519, 95%CI 1.239-1.861; Bayes RR&#x02009;=&#x02009;1.380, 95%CrI 0.981-1.944). Dapagliflozin-prescribed patients were also more likely to have a worse NYHA class at 6 months (OR&#x02009;=&#x02009;1.540, 95%CI 1.208-1.962; Bayes OR&#x02009;=&#x02009;1.425, 95%CrI 1.098-1.781).</p></sec><sec><title>Conclusion</title><p>CHF patients prescribed with dapagliflozin had poorer outcomes than their empagliflozin-prescribed peers over the initial 6 months of treatment. Data emphasize a need for a direct randomized comparison of the two treatments in this setting.</p></sec></abstract></article-meta></front><body><p>The current guidelines of the European Society of Cardiology (ESC) (<xref rid="R1" ref-type="bibr">1</xref>) for the management of patients with heart failure (HF) denote two sodium-glucose co-transporter 2 inhibitors (SGLT2i) &#x02013; dapagliflozin and empagliflozin &#x02013; as the only pharmacological options with a disease-modifying effect in chronic heart failure (CHF) across the entire range of left ventricular ejection fraction (LVEF) values. Hence, it is strongly recommended (<xref rid="R1" ref-type="bibr">1</xref>) that patients with reduced (HFrEF, LVEF&#x02264;40%), mildly reduced (HFmrEF, LVEF 41%-49%), or preserved (HFpEF, LVEF&#x02265;50%) ejection fraction should receive these treatments.</p><p>A serendipitous observation of cardiac benefits in type 2 diabetes (T2DM) patients treated with dapagliflozin or empagliflozin (<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>), and subsequent pivotal trials specifically in patients with CHF (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>) boosted extensive mechanistic research. Although many elements might not have been fully elucidated, it is obvious that cardiovascular and renal benefits of SGLT2 inhibition arise from a multitude of (sub)cellular effects in the kidney, heart, and other tissues where fundamental biological processes (eg, metabolic and ionic homeostasis, cell-cycle regulation, apoptosis, autophagy, energetic metabolism, and mitochondrial function) are affected, resulting in organ/system changes like increased blood oxygen-carrying capacity, reduced tissue fat, improved glucose control, increased diuresis, reduced intravascular volume, improved endothelial function, improved ventricular loading conditions and work efficiency, and many others, eventually resulting in improved cardiovascular and renal health (<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>). Currently, it is implicitly understood that the reported effects/mechanisms are due to the concept of &#x0201c;SGTL2 inhibition;&#x0201d; however, at least some effects might not be comparably intense for different compounds of the gliflozin class (<xref rid="R10" ref-type="bibr">10</xref>). In a clinical sense, and specifically in the CHF setting, the two approved gliflozins (dapagliflozin, empagliflozin) yield comparable benefits, with comparable safety profiles [pivotal clinical trials (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>), and <italic>post-hoc</italic> evaluations (<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>)], hence neither drug is preferred by the ESC guidelines (<xref rid="R1" ref-type="bibr">1</xref>). Still, based on small differences in the effects between dapagliflozin and empagliflozin (vs placebo) in pivotal trials, it has been suggested that in some health care systems cost-effectiveness of dapagliflozin could be somewhat more favorable than that of empagliflozin (<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>). On the other hand, a recent pharmacoepidemiological study suggested a 10% lower relative risk (RR) of hospitalization (95%CI 6% to 14%) and a 9% lower risk of all-cause death (95%CI 0 to 18%) within 1 year in patients prescribed with empagliflozin vs those prescribed with dapagliflozin (<xref rid="R15" ref-type="bibr">15</xref>). Considering that the study was based on administrative data, the suggested mild benefit in favor of empagliflozin should be viewed with caution (<xref rid="R15" ref-type="bibr">15</xref>).</p><p>We aimed to assess the relative efficacy of dapagliflozin vs empaglifozin in a cohort of routinely treated CHF patients. Based on the pivotal trial data (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>), we expected that the two treatments would be comparable in this respect, but we did not intend to test any formal hypothesis. Rather, we considered it reasonable to rely upon numerical trends/effect estimates as supportive or opposing to this assumption.</p><sec sec-type="methods"><title>Patients and methods</title><sec><title>Study outline</title><p>The present analysis is based on data routinely collected in a registry of CHF patients maintained at the Dubrava University Hospital, Zagreb, Croatia (the CaRD registry, NCT06090591), and was approved by the Institutional Ethics Committee (2022/1403-01). In line with the Institution&#x02019;s teaching status, all patients consented to the use of their anonymized data for the research and publishing purposes. Eligible for the analysis were patients started on dapagliflozin or empagliflozin between January 1, 2022 and July 31, 2023. Owing to the timing of regulatory approvals of the two drugs in treatment of CHF, in some patients SGLT2i were started after the commencement of other CHF treatments, ie, with a lag of a minimum 1 month and up to 10 months (prevalent patients), whereas in others SGLT2i were started together with other CHF treatments, ie, immediately upon the CHF diagnosis (incident patients). In the first step, these two patient subsets were analyzed separately (referred to as &#x0201c;Study 1&#x0201d; [prevalent patients] and Study 2 [incident patients]). Since the estimates generated in Study 1 and Study 2 were reasonably similar, data were merged and analyzed jointly (prevalent&#x02009;+&#x02009;incident patients). Finally, we explored potential modification of the dapagliflozin vs empagliflozin outcomes by chronic kidney disease (CKD or preserved renal function), and by the baseline LVEF (HFrEF or HFm/pEF).</p></sec><sec><title>Patients and patient management</title><p>The CaRD registry was set up to capture adult CHF patients (&#x02265;18 years of age) treated with the new generation of disease-modifying treatments. The present analysis focused on patients started on SGLT2i specifically for the treatment of CHF, in line with the ESC recommendations (<xref rid="R1" ref-type="bibr">1</xref>), between January 1 2022 and July 31, 2023. The patients were included if they (i) had a relatively shorter history of CHF at the commencement of SGLT2i (ie, &#x02264;18 months) to avoid potential confounding arising from possible imbalances in the burden of previous disease duration or other guideline-directed medical therapy (GDMT); and (ii) were free of conditions that could have affected life expectancy/evolution of CHF but might not have been controllable in the data analysis (ie, active malignant disease, on-going or recent anti-cancer treatment, HIV infection or pharmacological immunosuppression [transplant recipients, systemic inflammatory diseases]).</p><p>The registry included patients managed by five comparably experienced cardiologists specialized in heart failure. All diagnostic work-up and criteria, follow-up, and pharmacological and non-pharmacological treatments were implemented in line with the actual ESC guidelines (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R16" ref-type="bibr">16</xref>). Medical histories, comorbidities, and treatments were regularly updated. Heart failure was verified based on the functional status with New York Heart Association (NYHA) classification, echocardiographic assessments and estimated LVEF, and serum levels of the N-terminal fragment of the brain natriuretic peptide (NT-proBNP) (&#x0003e;600 pg/mL if with ongoing atrial flutter or fibrillation, &#x0003e;300 pg/mL otherwise). Other diagnostic work-up (eg, electrophysiological, laboratory, imaging) was steered by the managing cardiologist, in line with the individual patient particulars. The treatment of specifically CHF followed the guidelines (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R16" ref-type="bibr">16</xref>): (i) in patients with HFrEF, disease-modifying treatments were introduced and dosed on the discretion of the managing cardiologist in line with the patients&#x02019; status, response to therapy, or possible contraindications; (ii) since in patients with HFmrEF or HFpEF these compounds are not considered effective (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R16" ref-type="bibr">16</xref>), their use was based on the managing cardiologist discretion, and largely determined by comorbidities; (iii) implantable cardiac defibrillator devices were recommended to all patients with HFrEF of ischemic etiology and LVEF&#x02264;35% despite at least 3 months of GDMT treatment, and were considered in patients with HFrEF of non-ischemic etiology under the same conditions; (iv) diuretics were used in line with the recommendations (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R16" ref-type="bibr">16</xref>). With respect specifically to the use of SGLT2i: (i) the decision to commence treatment, the choice of a specific compound and posology were based on the managing cardiologist&#x02019;s discretion, in line with the recommendations (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R16" ref-type="bibr">16</xref>), the individual patient&#x02019;s characteristics, and the approved product labels (contraindications, special warnings, and precautions to use) (<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>); (ii) at the start of treatment, the information on demographics, ongoing treatments, comorbidities, and medical histories was updated (particularly, possible hospitalizations or emergency department visits for HF, cardio- or neurovascular incidents, and occurrence of urinary tract infections over the preceding 12 months); renal function (estimated glomerular filtration rate, eGFR, by the CKD-EPI 2021 equation), LVEF and NYHA class were reassessed, and NT-proBN<italic>P</italic> values were again measured. Registry data were updated through routine or unscheduled patient visits, on the occasion of emergency department visits or hospitalizations for heart failure, and through periodic checks of the hospital information system to capture other visits/hospitalizations (for any reason). Regarding specifically the use of SGLT2i as newly approved treatments in this indication, the time of their commencement was defined as &#x0201c;baseline&#x0201d; (new-user design). The subsequent visits were scheduled at varying time intervals, depending on the individual patient particulars, but all were scheduled for a control visit at 6 months after the start of treatment, as a standard routine procedure. Patients were reminded about the scheduled control visit (telephone, e-mail), typically around 10 days before the scheduled visit, or at the due date (if skipped) at the latest. The control visit included i) update of medical histories, ii) clinical evaluation and NYHA class, iii) LVEF assessment, iv) NT-proBNP measurement, v) eGFR re-estimation, vi) inquiries about possible intercurrent events, particularly in case of identified &#x0201c;other visits&#x0201d; or interventions not directly related to CHF.</p></sec><sec><title>Outcomes</title><p>The study period was limited to 6 months to minimize the interference of intercurrent events (particularly possible end of treatment or switching between treatments). The primary outcome was a composite of all-cause mortality and major adverse cardiovascular events (MACE) during this period, and was preferred to avoid bias arising from competing events. We preferred all-cause over cause-specific mortality to avoid misclassification bias arising from uncertainty in the detection of the actual causes of death that may occur in a &#x0201c;real-life&#x0201d; setting, particularly in the case of out-of-the hospital deaths. For in-hospital deaths, events and timing were identified directly, whereas out-of-the hospital deaths were assessed through the contacts with the next of kin and death certificates. MACE was defined as follows: (i) CHF deterioration &#x02013; hospitalization or emergency department visit for HF; ambulatory visits outside the scheduled visits due to symptom intensification; (ii) acute myocardial infarction/acute coronary syndrome; (iii) cerebrovascular incidents/transitory ischemic attack; (iv) pulmonary embolism; (v) deep vein thrombosis. MACE events/timing were ascertained directly or through hospital information system. The incidence of MACE was determined as a proportion of patients with at least one MACE (only a few repeated events were observed). The secondary outcome was NYHA class at the visit at 6 months. To avoid selection bias, we assigned NYHA class 5 to patients who died during the study period; assuming that the probability of death could have been affected by the assigned SGLT2i, the analysis of only survivors could have been biased, since they would have been selected by the less severe disease, and a treatment with a higher mortality would have had better NYHA class results. Other outcomes were recorded only in survivors (at the control visit): (i) NT-proBNP levels; (ii) LVEF; and (iii) eGFR.</p></sec><sec><title>Statistical considerations</title><p>We did not calculate the sample size but deemed that the data at hand could still provide a meaningful insight into relative efficacy of the two SGLT2i: i) the included patients displayed a wide range of LVEF values; hence, we expected the incidence of the primary outcome in the range of 10%-15% over the observed 6 months, and expected it to be fairly comparable in the two treatment arms; ii) in Study 1 (prevalent patients), and overall, this would have meant a number of events enabling rather robust proportions, where a few events more or less occurring by chance in either arm would not have altered the relationship between the two treatments substantially.</p><p>We used optimization-based weighting (<xref rid="R19" ref-type="bibr">19</xref>) to balance the covariates between the dapaglifloizin and empagliflozin-treated patients, separately in Study 1 (prevalent) and Study 2 (incident) with average treatment effect (ATE) as the estimand. The method is based on the convex optimization problem, and finds the weights of minimum variance that balance the empirical distribution of the observed covariates to the prespecified levels (<xref rid="R19" ref-type="bibr">19</xref>). It was implemented in package <italic>optweight</italic> (<xref rid="R20" ref-type="bibr">20</xref>) in R (<xref rid="R21" ref-type="bibr">21</xref>), and standardized mean differences &#x0003c;0.1 indicated adequate balance. A total of 41 covariates (potential confounders) were addressed, including demographics, CHF characteristics (NYHA class, LVEF values, NT-proBNP levels, CHF-related events over the preceding 12 months), comorbidities, and concomitant pharmacological and non-pharmacological treatments. There were no missing data on any of the considered covariates. Primary analysis of the primary and secondary outcomes was done separately in Study 1 and Study 2. Secondary analysis considered joint data (i) as if coming from a single study (&#x0201c;na&#x000ef;ve&#x0201d; approach), (ii) as a fixed-effect one-stage individual-patient data meta-analysis, and (iii) as a mixed-effects meta-analysis (random study effect). To explore effect modification by CKD and LVEF, dapagliflozin- and empagliflozin-treated patients (prevalent&#x02009;+&#x02009;incident) were balanced on the same covariates separately in patients with and without CKD, and those with HFrEF and those with HFm/pEF. The analytical model included an interaction term between treatment and CKD or LVE category, so that dapagliflozin vs empagliflozin estimates could be generated in each subset separately.</p><p>Weighted regression models were fitted to (i) probability of the primary outcome (log-binomial); (ii) probability of having a more severe NYHA class (cumulative logit). The model for NYHA included baseline NYHA as a covariate. All models employed robust (sandwich) variance estimation and Gauss-Hermite quadrature approximation. All analyses were repeated by fitting Bayesian models (except for the effect modification analysis) since they are generally more conservative, and we used a moderately informed skeptical normal prior for ln(RR)/ln(OR) centered at 0.0 [N(0, 0.355)] (assigns 95% probability to RR or OR between 0.5 and 2.0) &#x02013; in line with the assumption of comparable treatment outcomes. The analysis was done on the intent-to-treat basis (in agreement with the &#x0201c;treatment policy estimand&#x0201d;) (<xref rid="R22" ref-type="bibr">22</xref>): patients were considered as dapagliflozin- or empagliflozin-treated based on the initially assigned treatment. Other outcomes are summarized by treatment. We used SAS 9.4 for Windows (SAS Inc., Cary, NC) <italic>proc glimmix</italic> and <italic>proc genmod</italic>, and package <italic>brms</italic> (<xref rid="R23" ref-type="bibr">23</xref>) in R.</p></sec><sec><title>Sensitivity analysis</title><p>Having in mind residual confounding as an inherent problem of observational studies, we assumed that the present outcomes &#x02013; regardless of whether suggesting similarity or differences between treatments &#x02013; would be biased, either toward or away from the null. Therefore, we conceived a hypothetical strong biasing effect (RR&#x02009;=&#x02009;1.40 regarding the primary outcome; OR&#x02009;=&#x02009;1.50 regarding the NYHA class) disfavoring one or the other treatment (overall prevalence 35%, with an imbalance of 1.5:1.0 in dapagliflozin-treated vs empagliflozin treated patients, or <italic>vice-versa</italic>), and planned to correct the observed effect estimates for this biasing effect (<xref rid="R24" ref-type="bibr">24</xref>) [package <italic>episensr</italic> (<xref rid="R25" ref-type="bibr">25</xref>) in R]. In case of difference between treatments, we also calculated the E-value - the size of the confounding effect (on the relative risk scale) needed to explain away the observed treatment differences (<xref rid="R26" ref-type="bibr">26</xref>).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient eligibility and characteristics</title><p>A total of 961 patients were eligible for the analysis, mostly in Study 1(<xref rid="F1" ref-type="fig">Figure 1</xref>), with comparable numbers prescribed with dapagliflozin (393 in Study 1, 126 in Study 2) and empagliflozin (328 in Study 1, 114 in Study 2) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Before weighting, dapagliflozin- and empagliflozin-prescribed patients differed regarding a number of characteristics: i) in Study 1 (prevalent patients) (<xref rid="T1" ref-type="table">Table 1</xref>), particularly regarding the prevalence of HFpEF/HFmEF/HFrEF, average LVEF, prevalence of chronic kidney disease, and average eGFR (d &#x02265;0.300) (<xref rid="T1" ref-type="table">Table 1</xref>); (ii) in Study 2 (incident patients) (<xref rid="T2" ref-type="table">Table 2</xref>), particularly regarding the prevalence of LVEF&#x02264;40% and average LVEF, NYHA class, NT-proBNP concentration, prevalence of dyslipidemia, atrial fibrillation, coronary artery disease, hospitalization for HF as the occasion for CHF diagnosis, and the initiated treatment with mineralocorticoid receptor antagonists, diuretics, and antiplatelets (d &#x02265;0.300) (<xref rid="T2" ref-type="table">Table 2</xref>). However, weighting enabled a fully adequate balance on all covariates in both studies: all d &#x0003c;0.1 (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>).</p><fig position="float" id="F1" fig-type="figure"><label>Figure 1</label><caption><p>Outline of the present analysis. Included were chronic heart failure (CHF) patients embraced in an institutional registry, started on sodium-glucose co-transporter type 2 inhibitors (SGLT2i) dapagliflozin or empagliflozin, either with a delay vs the CHF diagnosis (prevalent patients, Study 1), or immediately after the CHF diagnosis (incident patients, Study 2). At the start of SGLT2i treatment (baseline), patients prescribed the two SGLT2i were mutually balanced (by optimization-based weighting) on a number of covariates, and were assessed at a control visit 6 months later. MACE &#x02013; major adverse cardiovascular events; NT-proBNP &#x02013; N-terminal pro-brain natriuretic polypeptide; NYHA &#x02013; New York Heart Association.</p></caption><graphic xlink:href="CroatMedJ_66_0135-F1" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics in Study 1 by sodium-glucose transporter 2 inhibitor (SGLT2i) &#x02013; dapagliflozin (DAPA) or empagliflozin (EMPA) &#x02013; before and after optimization weighting<sup>*&#x02020;&#x02021;</sup></p></caption><table frame="hsides" rules="groups"><col width="122" span="1"/><col width="68" span="1"/><col width="68" span="1"/><col width="32" span="1"/><col width="68" span="1"/><col width="68" span="1"/><col width="32" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Before weighting<hr/></th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">After weighting<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">d</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">d</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">393<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">328<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">393<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">328<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (years)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11 (29-90)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11 (27-90)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.033<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">260 (66.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">216 (65.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.006<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.041<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF p EF (LVEF 50%-78%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">85 (21.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">110 (33.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.269<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF mr EF (LVEF 41%-49%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54 (13.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56 (17.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.092<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF r EF (LVEF&#x02264;40%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">254 (64.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">162 (49.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.312<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.5&#x02009;&#x000b1;&#x02009;12.4 (15-78)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.7&#x02009;&#x000b1;&#x02009;11.8 (19-75)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.348<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.3&#x02009;&#x000b1;&#x02009;12.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.6&#x02009;&#x000b1;&#x02009;11.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22 (5.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20 (6.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.069<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">188 (47.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">177 (54.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.123<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.020<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">159 (40.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">117 (35.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.099<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.004<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24 (6.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (4.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.083<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.018<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NT-proBNP (pg/mL)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2530 (48-35000)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1798 (55-35000)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2237<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2323<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(NT-proBNP)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.859&#x02009;&#x000b1;&#x02009;1.303<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.579&#x02009;&#x000b1;&#x02009;1.205<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.223<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.713&#x02009;&#x000b1;&#x02009;1.288<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.750&#x02009;&#x000b1;&#x02009;1.216<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.4 (16.8-65.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.6 (16.7-53.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(BMI)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.362&#x02009;&#x000b1;&#x02009;0.177<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.398&#x02009;&#x000b1;&#x02009;0.190<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.194<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.357&#x02009;&#x000b1;&#x02009;0.181<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.381&#x02009;&#x000b1;&#x02009;0.187<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chronic kidney disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">199 (50.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">108 (32.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.365<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">eGFR (mL/min/1.73m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59.9&#x02009;&#x000b1;&#x02009;24.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67.6&#x02009;&#x000b1;&#x02009;20.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.344<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.1&#x02009;&#x000b1;&#x02009;23.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.7&#x02009;&#x000b1;&#x02009;21.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.030<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Diabetes mellitus<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">77 (19.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">83 (25.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.137<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">177 (45.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">140 (42.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.057<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prediabetes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">139 (35.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">105 (32.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.071<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hypertension<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">352 (89.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">304 (92.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.110<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">91.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.031<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">UTI over previous 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39 (9.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31 (9.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.016<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.007<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dyslipidemia<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">290 (73.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">246 (75.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.028<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">73.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">75.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Atrial fibrillation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">202 (51.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">169 (51.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.002<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">52.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.039<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hemoglobin (g/L)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">134&#x02009;&#x000b1;&#x02009;19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">134&#x02009;&#x000b1;&#x02009;18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.003<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">134&#x02009;&#x000b1;&#x02009;18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">133&#x02009;&#x000b1;&#x02009;18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.071<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anemic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">149 (37.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">103 (31.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.137<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">35.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.026<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Asthma/COPD<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61 (15.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40 (12.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.096<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.062<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Coronary artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">190 (49.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">164 (50.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.008<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.027<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5 (1.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.004<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (3.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21 (6.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.131<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.046<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of CVI/TIA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50 (12.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29 (8.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.125<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.065<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CVI/TIA at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.048<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.064<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DVT/PE over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (1.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11 (3.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.160<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.098<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Peripheral artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86 (21.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65 (19.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.051<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.003<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">HHF over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">177 (45.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (56.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.222<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.040<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">One<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">156 (39.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">114 (34.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.102<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.007<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Two<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48 (12.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26 (7.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.143<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.022<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Three<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10 (2.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (1.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.098<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.057<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Four<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (0.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.101<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.048<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">ER for HF over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">176 (44.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">170 (51.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.141<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.028<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">One<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">159 (40.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">130 (39.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.017<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.037<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Two<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49 (12.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27 (8.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.139<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.059<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Three<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.129<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.089<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Four<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.124<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.088<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HHF at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">117 (29.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">85 (25.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.086<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CRT or ICD or pacemaker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">102 (25.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">75 (22.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.072<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.028<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACEi or AT1 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">221 (56.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">200 (61.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.096<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">58.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.038<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sacubitril-valsartan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">128 (32.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100 (30.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.045<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MRA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">321 (81.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">265 (80.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.023<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">82.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.051<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diuretic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">326 (82.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">239 (72.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.245<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">79.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">77.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.061<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Beta-blocker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">354 (90.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">301 (91.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.059<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">91.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.067<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCB<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80 (20.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">74 (22.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.054<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.027<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Dyslipidemia treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">128 (32.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">93 (28.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.092<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.065<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">High-potency statin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">243 (61.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">209 (63.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.039<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.027<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Statin&#x02009;+&#x02009;ezetimib<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22 (5.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26 (7.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.093<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.067<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Metformin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">83 (21.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89 (27.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.141<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.047<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">GLP-1 agonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26 (6.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47 (14.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.254<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.033<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Inzulin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26 (6.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18 (5.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.057<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.009<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other antidiabetic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29 (7.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (5.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.091<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.043<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Anticoagulation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">176 (44.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">155 (47.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.050<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.002<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Warfarin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54 (13.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36 (11.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.084<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.058<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DOAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">163 (41.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">137 (41.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.006<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.040<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Dual antiplatelet/equivalent<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">347 (82.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">273 (83.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">82.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">83.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.043<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aspirin + P2Y12 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42 (10.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39 (11.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.038<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.012<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">OAC + P2Y12 antagonist</td><td valign="top" align="left" rowspan="1" colspan="1">27 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.085</td><td valign="top" align="left" rowspan="1" colspan="1">7.0</td><td valign="top" align="left" rowspan="1" colspan="1">5.0</td><td valign="top" align="left" rowspan="1" colspan="1">0.085</td></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ACEi/AT1 &#x02013; angiotensin converting enzyme inhibitor/angiotensin receptor type 1; ACS/AMI &#x02013; acute coronary syndrome/acute myocardial infarction; BMI &#x02013; body mass index; CCB &#x02013; calcium channel blocker; COPD &#x02013; chronic obstructive pulmonary disease; CRT &#x02013; cardiac resynchronization therapy; CVI/TIA &#x02013; cerebrovascular insult/transitory ischemic attack; DOAC &#x02013; direct oral anticoagulants; DVT/PE &#x02013; deep vein thrombosis/pulmonary embolism; eGFR &#x02013; estimated glomerular filtration rate; ER &#x02013; emergency department visit; GLP1 &#x02013; glucagon-like polypeptide 1; HF p/mr/r EF &#x02013; heart failure with preserved/moderately reduced /reduced ejection fraction; HHF &#x02013; hospitalization for heart failure; ICD &#x02013; implantable cardioverter defibrillator; LVEF &#x02013; left ventricular ejection fraction; MRA &#x02013; mineralocorticoid receptor antagonist; NT-proBNP &#x02013; N-terminal pro-brain natriuretic polypoeptide; NYHA &#x02013; New York Heart Association; OAC &#x02013; oral anticoagulant; UTI &#x02013; urinary tract infection.</p><p>&#x02020;Raw data (before weighting) are count (percent), median (range) or mean&#x000b1;SD (range). Adjusted Dapa (after weighting) data are (weighted) percentages, mean&#x000b1;SD, or geometric mean (for ln-transformed continuous variables). Shown are also standardized mean differences (d): where d &#x0003c;0.1, balance between DAPA and EMPA-treated subjects is considered adequate.</p><p>&#x02021;Effective sample size after weighting: dapagliflozin n&#x02009;=&#x02009;360 (weights mean 1.0 SD 0.304, range 0.19-2.00), empagliflozin n&#x02009;=&#x02009;293 (weights mean 1.0 SD 0.346, range 0.12-2.09).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Patient characteristics in Study 2 by sodium-glucose transporter 2 inhibitor (SGLT2i) &#x02013; dapagliflozin (DAPA) or empagliflozin (EMPA) &#x02013; before and after optimization weighting*</p></caption><table frame="hsides" rules="groups"><col width="104" span="1"/><col width="65" span="1"/><col width="68" span="1"/><col width="30" span="1"/><col width="50" span="1"/><col width="49" span="1"/><col width="30" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Before weighting<hr/></th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">After weighting<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">d</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">d</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">124<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">116<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">124<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">116<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (years)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66&#x02009;&#x000b1;&#x02009;13 (31-87)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64&#x02009;&#x000b1;&#x02009;12 (27-89)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.112<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65&#x02009;&#x000b1;&#x02009;14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65&#x02009;&#x000b1;&#x02009;12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.029<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86 (69.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">85 (73.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.087<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.048<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF r EF (LVEF&#x02264;40%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">105 (84.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67 (57.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.623<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF mr/p EF (LVEF&#x0003e;40%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19 (15.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49 (42.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.623<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF 50%-78%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12 (9.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29 (25.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16,1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF 41%-49%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (5.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20 (17.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF&#x02264;40%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">105 (84.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67 (57.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.4&#x02009;&#x000b1;&#x02009;9.9 (15-62)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.7&#x02009;&#x000b1;&#x02009;12.7 (15-75)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.647<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36.8&#x02009;&#x000b1;&#x02009;11.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.1&#x02009;&#x000b1;&#x02009;12.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.031<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (4.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (6.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.053<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.059<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42 (33.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59 (50.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.349<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.040<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63 (50.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42 (36.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.298<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.033<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13 (10.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8 (6.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.128<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.035<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NT-proBNP (pg/mL)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4174 (34-35000)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2639 (250-35000)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3271<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3301<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(NT-proBNP)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.297&#x02009;&#x000b1;&#x02009;1.228<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.912&#x02009;&#x000b1;&#x02009;1.112<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.329<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.093&#x02009;&#x000b1;&#x02009;1.263<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.102&#x02009;&#x000b1;&#x02009;1.086<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.008<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.4 (15-50.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.9 (19.5-55.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(BMI)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.364&#x02009;&#x000b1;&#x02009;0.213<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.341&#x02009;&#x000b1;&#x02009;0.170<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.115<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.356&#x02009;&#x000b1;&#x02009;0.208<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.350&#x02009;&#x000b1;&#x02009;0.172<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.031<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chronic kidney disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33 (26.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34 (29.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.060<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">eGFR (mL/min/1.73m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.8&#x02009;&#x000b1;&#x02009;22.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">74.0&#x02009;&#x000b1;&#x02009;21.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.099<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72.3&#x02009;&#x000b1;&#x02009;23.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72.9&#x02009;&#x000b1;&#x02009;21.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.029<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Diabetes mellitus<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37 (29.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41 (35.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.118<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41 (33.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48 (41.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.173<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prediabetes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46 (37.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27 (23.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.304<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hypertension<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89 (71.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">91 (78.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.155<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">74.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.047<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dyslipidemia<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69 (55.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38 (30.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.355<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.064<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Atrial fibrillation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">84 (72.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27 (23.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.025<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hemoglobin (g/L)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">137&#x02009;&#x000b1;&#x02009;18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">139&#x02009;&#x000b1;&#x02009;19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.133<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">137&#x02009;&#x000b1;&#x02009;18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">138&#x02009;&#x000b1;&#x02009;20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.051<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anemic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37 (29.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36 (31.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.026<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.043<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Coronary artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61 (49.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">79 (68.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.391<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.048<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8 (6.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (14.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Carotide/peripheral artery<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25 (20.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16 (13.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.170<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18,1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.054<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of CVI/TIA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (11.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CVI/TIA at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Peripheral artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (12.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (12.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HHF at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71 (57.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39 (33.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.488<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CRT or ICD or pacemaker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (12.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (12.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">UTI over previous 12 mo<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11 (8.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9 (7.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.040<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACEi or AT1 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">87 (70.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">91 (78.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.191<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">73.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">75.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sacubitril-valsartan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29 (23.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (14.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.224<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.035<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MRA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">111 (89.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86 (74.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.407<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">82.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">81.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.038<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diuretic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">96 (77.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65 (56.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.466<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.026<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Beta-blocker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">117 (94.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">102 (87.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.228<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">92.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.087<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCB<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25 (20.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21 (18.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.050<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.049<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dyslipidemia treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">83 (66.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">88 (75.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.199<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.049<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41 (33.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28 (24.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">High-potency statin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76 (61.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">83 (71.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Statin&#x02009;+&#x02009;ezetimib<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (5.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antidiabetic treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24 (19.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37 (31.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.290<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.048<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Metformin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16 (12.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32 (27.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">GLP-1 agonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11 (8.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8 (6.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Inzulin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anticoagulation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46 (37.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31 (26.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.224<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.044<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">78 (62.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">85 (73.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Warfarin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (4.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DOAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40 (32.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25 (21.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antiplatelet<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40 (32.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65 (56.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.493<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.063<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">84 (67.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51 (44.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aspirin + P2Y12 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32 (25.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54 (46.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">P2Y12 antagonist</td><td valign="top" align="left" rowspan="1" colspan="1">8 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;</td><td valign="top" align="left" rowspan="1" colspan="1">5.9</td><td valign="top" align="left" rowspan="1" colspan="1">9.2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ACEi/AT1 &#x02013; angiotensin converting enzyme inhibitor/angiotensin receptor type 1; ACS/AMI &#x02013; acute coronary syndrome/acute myocardial infarction; BMI &#x02013; body mass index; CCB &#x02013; calcium channel blocker; COPD &#x02013; chronic obstructive pulmonary disease; CRT &#x02013; cardiac resynchronization therapy; CVI/TIA &#x02013; cerebrovascular insult/transitory ischemic attack; DOAC &#x02013; direct oral anticoagulants; DVT/PE &#x02013; deep vein thrombosis/pulmonary embolism; eGFR &#x02013; estimated glomerular filtration rate; ER &#x02013; emergency department visit; GLP1 &#x02013; glucagon-like polypeptide 1; HF p/mr/r EF &#x02013; heart failure with preserved/moderately reduced /reduced ejection fraction; HHF &#x02013; hospitalization for heart failure; ICD &#x02013; implantable cardioverter defibrillator; LVEF &#x02013; left ventricular ejection fraction; MRA &#x02013; mineralocorticoid receptor antagonist; NT-proBNP &#x02013; N-terminal pro-brain natriuretic polypeptide; NYHA &#x02013; New York Heart Association; OAC &#x02013; oral anticoagulant; UTI &#x02013; urinary tract infection</p><p>&#x02020;Raw data (before weighting) are count (percent), median (range) or mean&#x000b1;SD (range). Adjusted (after weighting) data are (weighted) percentages, mean&#x000b1;SD, or geometric mean (for ln-transformed variables). Shown are also standardized mean differences (d): where d &#x0003c;0.1, balance between DAPA and EMPA-treated subjects is considered adequate. Considering the limited number of patients, some characteristics were collapsed into coarser categories for weighting (denoted by the depicted d-values), but data on included subcagetories (not used for weighting) are also shown.</p><p>&#x02021;Effective sample size after weighting: dapagliflozin n&#x02009;=&#x02009;96.6 (weights mean 1.0 SD 0.537, range 0.13-2.82), empagliflozin n&#x02009;=&#x02009;93.1 (weights mean 1.0 SD 0.498, range 0.10-2.15).</p></table-wrap-foot></table-wrap></sec><sec><title>Primary and secondary outcomes: primary analysis</title><p>Control visits were performed within a narrow range of 161/163 to 196/198 days since the start of SGLT2i treatment (<xref rid="T3" ref-type="table">Table 3</xref>). In Study 1, 82 patients (11.4%) experienced the primary outcome: 38 patients died and 53 experienced at least one MACE event, predominantly HF deterioration (<xref rid="T3" ref-type="table">Table 3</xref>). The incidence of the primary outcome and its components was somewhat higher in dapagliflozin-prescribed than in empagliflozin -prescribed patients (13.7% vs 8.5% raw data, 12.8% vs 9.2% weighted data) (<xref rid="T3" ref-type="table">Table 3</xref>). Also, dapagliflozin-prescribed patients were more likely to present with a worse NYHA class (<xref rid="T3" ref-type="table">Table 3</xref>). In Study 2, only 20 patients experienced the primary outcome (8 died, 14 with at least one MACE event) (<xref rid="T3" ref-type="table">Table 3</xref>) &#x02013; still, the incidence of the primary outcome was higher in dapagliflozin-prescribed patients (11.3% vs 5.2% regarding both raw and weighted data) (<xref rid="T3" ref-type="table">Table 3</xref>). Again, dapagliflozin-prescribed patients were more likely to present with a worse NYHA class (<xref rid="T3" ref-type="table">Table 3</xref>). For the primary outcome, adjusted relative risk point-estimates (dapagliflozin vs empagliflozin) were all &#x0003e;1.28 in both studies (<xref rid="F2" ref-type="fig">Figure 2</xref>), but with wide confidence intervals (limited sample size/number of events). For the secondary outcome, in Study 1 both the adjusted frequentist (OR&#x02009;=&#x02009;1.552, 95%CI 1.142-2.108) and the Bayesian estimates (OR&#x02009;=&#x02009;1.445, 95%CrI 1.113-1.874) suggested higher odds of a worse NYHA class in dapagliflozin-prescribed patients (<xref rid="F2" ref-type="fig">Figure 2</xref>). Point-estimates were similar in Study 2, but confidence intervals extended to &#x0003c;1.0 (<xref rid="F2" ref-type="fig">Figure 2</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Primary and secondary outcomes in Study 1 and Study 2: cumulative incidence of death/major adverse cardiovascular events (MACE) between start of treatment with dapagliflozin (DAPA) or empagliflozin (EMPA) and control visit (at 6 months &#x000b1;2 weeks) (primary), and New York Heart Association (NYHA) class at the control visit (secondary). Data are count (percent) or weighted percent, and median (range) for timing of the control visit</p></caption><table frame="hsides" rules="groups"><col width="124" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="65" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="65" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Study 1<hr/></th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Study 2<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Raw data (unadjusted)<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Weighted data (adjusted)<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Raw data (unadjusted)<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Weighted data (adjusted<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">393<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">328<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">393<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">328<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">124<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">116<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">124<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">116<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Control visit timing (days)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (163-196)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (161-196)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (163-196)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (161-196)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (163-197)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">183 (165-198)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">184 (163-197)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">183 (165-198)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died or MACE to day 160<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54 (13.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28 (8.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.8%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.2%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (11.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.2%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.3%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.2%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25 (6.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13 (4.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (4.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.7%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.2%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MACE<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36 (9.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (5.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.3%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10 (8.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.5%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.9%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Heart failure deterioration<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Acute myocardial infarction<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cerebrovascular insult<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Deep vein thrombosis<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">NYHA class at control visit<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">123 (31.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">153 (46.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63 (51.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">78 (69.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65.1%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">190 (48.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">137 (41.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.3%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47 (38.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31 (27.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.5%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43 (10.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22 (6.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.5%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (5.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.7%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12 (3.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died (considered as class &#x02018;5&#x02032;)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5.9%</td><td valign="top" align="left" rowspan="1" colspan="1">4.4%</td><td valign="top" align="left" rowspan="1" colspan="1">6 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3.7%</td><td valign="top" align="left" rowspan="1" colspan="1">2.2%</td></tr></tbody></table></table-wrap><fig position="float" id="F2" fig-type="figure"><label>Figure 2</label><caption><p>Summary of the adjusted (weighted) primary analysis (each study separately) of the primary (all-cause mortality/major adverse cardiovascular events, MACE) and secondary (New York Heart Association, NYHA, class at the control visit) outcomes. Effect estimates are for the dapagliflozin (DAPA) vs empagliflozin (EMPA) contrast: relative risks (RR) for the primary and odds ratios (OR) for the secondary outcome (OR&#x0003e;1.0 indicates higher odds of a worse NYHA class). Bayesian credible intervals are the highest posterior density intervals.</p></caption><graphic xlink:href="CroatMedJ_66_0135-F2" position="float"/></fig></sec><sec><title>Primary and secondary outcomes: secondary analysis and sensitivity to unmeasured confounding</title><p>In the combined weighted Study 1 and Study 2 data, all considered covariates were adequately balanced (all d &#x0003c;0.1) between dapagliflozin-prescribed (n&#x02009;=&#x02009;517) and empagliflozin-prescribed (n&#x02009;=&#x02009;444) patients (<xref rid="T4" ref-type="table">Table 4</xref>). Regardless of whether analyzed as a &#x0201c;single study,&#x0201d; or as a fixed-effect or mixed-effects one-stage individual patient data meta-analysis, regarding the primary outcome, all frequentist estimates were entirely &#x02265;1.0, suggesting around 51% higher risk of death/MACE in dapagliflozin-prescribed patients (<xref rid="F3" ref-type="fig">Figure 3</xref>). Bayesian estimates were somewhat lower, with lower limits of the 95%CrIs falling slightly &#x0003c;1.0 (<xref rid="F3" ref-type="fig">Figure 3</xref>). Regarding the secondary outcome, all frequentist and Bayesian estimates were entirely &#x0003e;1.0, suggesting around 54% (frequentist) or around 42% (Bayes) higher odds of having worse NYHA class in the dapagliflozin-prescribed patients (<xref rid="F3" ref-type="fig">Figure 3</xref>). Estimates corrected for a hypothetical strong confounding bias &#x0201c;disfavoring&#x0201d; dapagliflozin were only slightly smaller than the observed ones, and remained mainly entirely &#x0003e;1.0 or with lower bounds of the 95%CI/CrI only slightly &#x0003c;1.0 (<xref rid="F3" ref-type="fig">Figure 3</xref>, gray squares). Estimates corrected for the same hypothetical bias but &#x0201c;disfavoring&#x0201d; empagliflozin were slightly greater than the observed ones (<xref rid="F3" ref-type="fig">Figure 3</xref>, gray diamonds).The E-values suggested that a very strong confounding bias (association with both dapagliflozin and poor outcomes, on the relative risk scale between 1.820 and 2.168) would be needed to explain away the largest part of the observed point-estimates, ie, to &#x0201c;push&#x0201d; the point-estimates to RR/OR&#x02009;=&#x02009;1.10 (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Patient characteristics &#x02013; combined weighted Study 1 and Study 2 data by dapagliflozin (DAPA) or empagliflozin (EMPA). Data are (weighted) percentages, mean&#x000b1;SD, or geometric mean (for ln-transformed variables). Shown are also standardized mean differences (d): where d &#x0003c;0.1, balance between DAPA- and EMPA-treated patients is considered adequate*</p></caption><table frame="hsides" rules="groups"><col width="183" span="1"/><col width="68" span="1"/><col width="68" span="1"/><col width="33" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">d</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">517<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">444<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (years)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68&#x02009;&#x000b1;&#x02009;12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68&#x02009;&#x000b1;&#x02009;12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.005<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">SGLT2i start lagged vs other treatment (Study 1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">73.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.049<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">SGLT2i start with other treatments (Study 2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.049<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.045<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF r EF (LVEF&#x02264;40%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.004<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HF mr/p EF (LVEF&#x0003e;40%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.004<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF 50%-78%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.020<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF 41%-49%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.017<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF&#x02264;40%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.006<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">LVEF (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.4&#x02009;&#x000b1;&#x02009;12.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.7&#x02009;&#x000b1;&#x02009;11.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.024<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.067<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.003<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NYHA 4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.026<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NT-proBNP (pg/mL)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2450<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2545<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(NT-proBNP)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.804&#x02009;&#x000b1;&#x02009;1.291<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.842&#x02009;&#x000b1;&#x02009;1.193<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.031<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ln(BMI)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.371&#x02009;&#x000b1;&#x02009;0.188<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.373&#x02009;&#x000b1;&#x02009;0.184<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.011<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chronic kidney disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.007<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">eGFR (mL/min/1.73m<sup>2</sup>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65.3&#x02009;&#x000b1;&#x02009;23.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66.1&#x02009;&#x000b1;&#x02009;21.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.038<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Diabetes mellitus<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.005<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">42.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.006<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prediabetes<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.002<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hypertension<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">87.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.027<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dyslipidemia<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Atrial fibrillation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.024<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hemoglobin (g/L)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">135&#x02009;&#x000b1;&#x02009;18.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">135&#x02009;&#x000b1;&#x02009;18.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.030<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anemic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.011<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Coronary artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">52.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">53.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.028<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI over 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.031<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS/AMI at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.060<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Carotide/peripheral artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.020<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of CVI/TIA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.098<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CVI/TIA at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.034<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Peripheral artery disease<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.009<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">COPD /asthma<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.084<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">HHF / 12 months (includes index HHF for Study 2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.060<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.037<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.053<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.042<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">ER HF/ 12 months (includes index visit for Study 2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">57.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.044<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.022<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.074<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.085<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.077<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HHF at start of SGLT2i<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.012<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CRT or ICD or pacemaker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.021<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">UTI over previous 12 months<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.010<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACEi or AT1 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.045<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sacubitril-valsartan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.018<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MRA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">81.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.025<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diuretic<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">74.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.042<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Beta-blocker<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">91.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.029<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCB<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.034<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dyslipidemia treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">70.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.038<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.038<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">High-potency statin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">63.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.037<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Statin&#x02009;+&#x02009;ezetimib<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.000<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antidiabetic treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.026<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Metformin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.080<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">GLP-1 agonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.025<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Insulin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.004<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.039<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anticoagulation<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.019<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.019<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Warfarin<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.049<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DOAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">37.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.012<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antiplatelet/equivalent<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.003<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.003<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aspirin + P2Y12 antagonist<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-0.020<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">OAC + P2Y12 antagonist or P2Y12 antagonist</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">6.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.025</td></tr></tbody></table><table-wrap-foot><p>*Abbreviations: ACEi/AT1 &#x02013; angiotensin converting enzyme inhibitor/angiotensin receptor type 1; ACS/AMI &#x02013; acute coronary syndrome/acute myocardial infarction; BMI &#x02013; body mass index; CCB &#x02013; calcium channel blocker; COPD &#x02013; chronic obstructive pulmonary disease; CRT &#x02013; cardiac resynchronization therapy; CVI/TIA &#x02013; cerebrovascular insult/transitory ischemic attack; DOAC &#x02013; direct oral anticoagulants; DVT/PE &#x02013; deep vein thrombosis/pulmonary embolism; eGFR &#x02013; estimated glomerular filtration rate; ER &#x02013; emergency department visit; GLP1 &#x02013; glucagon-like polypeptide 1; HF p/mr/r EF &#x02013; heart failure with preserved/moderately reduced /reduced ejection fraction; HHF &#x02013; hospitalization for heart failure; ICD &#x02013; implantable cardioverter defibrillator; LVEF &#x02013; left ventricular ejection fraction; MRA &#x02013; mineralocorticoid receptor antagonist; NT-proBNP &#x02013; N-terminal pro-brain natriuretic polypeptide; NYHA &#x02013; New York Heart Association; OAC &#x02013; oral anticoagulant; UTI &#x02013; urinary tract infection</p></table-wrap-foot></table-wrap><fig position="float" id="F3" fig-type="figure"><label>Figure 3</label><caption><p>Summary of the adjusted (weighted) secondary analysis (pooled data) of the primary (all-cause mortality/major adverse cardiovascular events, MACE) and secondary (New York Heart Association, NYHA, class at the control visit) outcomes with sensitivity to unmeasured confounding. Effect estimates are for the dapagliflozin (DAPA) vs empagliflozin (EMPA) contrast: relative risks (RR) for the primary and odds ratios (OR) for the secondary outcome (OR&#x0003e;1.0 indicates higher odds of a worse NYHA class). Bayesian credible intervals are the highest posterior density intervals. Black squares (bars) denote observed effects. Gray squares (bars) and font denote estimates corrected for a hypothetical bias disfavoring dapagliflozin: (i) we assumed a strong residual confounding bias with an effect of RR&#x02009;=&#x02009;1.40 for the primary outcome and OR&#x02009;=&#x02009;1.50 for the secondary outcome, where the overall prevalence of the &#x0201c;biasing variables&#x0201d; is 35%, with a higher prevalence in dapagliflozin-treated than in empagliflozin-treated patients (ratio 1.5:1.0), ie, dapagliflozin 41.4% vs empagliflozin 27.5%. The observed effects were corrected for this hypothetical bias. Gray diamonds (bars) and font denote estimates corrected for the same hypothetical bias but under the assumption that it disfavored empagliflozin: &#x0201c;biasing variables&#x0201d; were assumed more prevalent in empagliflozin vs dapagliflozin-treated patients (ratio 1.5:1.0), ie, empagliflozin 42.3% vs dapagliflozin 28.6%. The E-values denote (on a risk ratio scale) the size of a confounding effect needed to explain away the largest part of the observed point-estimates, ie, to &#x0201c;push&#x0201d; them to RR/OR&#x02009;=&#x02009;1.10.</p></caption><graphic xlink:href="CroatMedJ_66_0135-F3" position="float"/></fig></sec><sec><title>Other outcomes</title><p>NT-proBNP levels, LVEF, and eGFR values at the control visit (survivors only) were similar between dapagliflozin-prescribed and empagliflozin -prescribed patients in both studies (Supplemental Material 1<xref rid="S16" ref-type="supplementary-material">(Supplemental Material 1)</xref>).</p></sec><sec><title>Exploration of effect modification by chronic kidney disease and ejection fraction</title><p>Fewer patients had CKD (dapagliflozin n&#x02009;=&#x02009;232, empagliflozin n&#x02009;=&#x02009;142) or HFm/pEF (dapagliflozin n&#x02009;=&#x02009;158, empagliflozin n&#x02009;=&#x02009;215) than a preserved renal function (dapagliflozin n&#x02009;=&#x02009;285, empagliflozin n&#x02009;=&#x02009;302) or HFrEF (dapagliflozin 359, empagliflozin n&#x02009;=&#x02009;229). Across the subsets, dapagliflozin and empagliflozin patients mildly to moderately differed on a range of baseline covariates, but were adequately balanced on all of them (Supplemental Material 2<xref rid="S16" ref-type="supplementary-material">(Supplemental Material 2)</xref>, Table B1 &#x02013; Table B4). In patients with CKD and in those with HFm/pEF, raw data indicated somewhat higher incidence of the primary outcome and of worse NYHA class in dapagliflozin- vs empagliflozin-prescribed patients (<xref rid="T5" ref-type="table">Table 5</xref>), but weighted data did not (<xref rid="T5" ref-type="table">Table 5</xref>). In patients with a preserved renal function, and in those with HFpEF, both raw and weighted data indicated worse outcomes with dapagliflozin vs empagliflozin (<xref rid="T5" ref-type="table">Table 5</xref>). In the fully adjusted analysis (<xref rid="F4" ref-type="fig">Figure 4</xref>): i) the primary outcome was similar for the two treatments in patients with CKD (RR&#x02009;=&#x02009;0.95, 95%CI 0.56-1.63) and in those with HFm/pEF (RR&#x02009;=&#x02009;0.98, 0.58-1.86), but was markedly higher with dapagliflozin in patients without CKD (RR&#x02009;=&#x02009;2.14, 1.14-3.99) and in those with HFrEF (RR&#x02009;=&#x02009;1.71, 0.98-3.02); ii) in both patients with (OR&#x02009;=&#x02009;1.39, 0.90-2.16) and without CKD (1.56, 1.11-2.21), dapagliflozin-prescribed patients had higher odds of a worse NYHA class than empagliflozin-prescribed patients. In patients with HFm/pEF, there was no difference between the treatments (OR&#x02009;=&#x02009;1.03, 0.67-1.58), but in patients with HFrEF, the odds of a worse NYHA class were higher with dapagliflozin than with empagliflozin (OR&#x02009;=&#x02009;1.76, 1.24-2.49).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Primary and secondary outcomes in patients with chronic kidney disease (CKD), patients with a preserved renal function, patients with mildly reduced or preserved left ventricular ejection fraction (LVEF) (HFm/pEF), and patients with a reduced ejection fraction (HFrEF): cumulative incidence of death/major adverse cardiovascular events (MACE) between the start of treatment with dapagliflozin (DAPA) or empagliflozin (EMPA) and control visit (at 6 months &#x000b1;2 weeks) (primary), and New York Heart Association (NYHA) class at the control visit (secondary). Data are count (percent) or weighted percent</p></caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="45" span="1"/><col width="45" span="1"/><col width="31" span="1"/><col width="33" span="1"/><col width="45" span="1"/><col width="45" span="1"/><col width="31" span="1"/><col width="33" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Subsets of CKD<hr/></th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Patients with CKD<hr/></th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Patients with preserved renal function<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">
<hr/>
</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Raw data<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Weighted data<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Raw data<hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Weighted data<hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">DAPA</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">EMPA</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">232<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">142<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">232<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">142<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">285<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">302<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">285<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">302<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died or MACE<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">35 (15.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19 (13.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.2%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33 (11.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (5.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.1%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (7.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9 (6.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (4.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (2.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.1%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MACE<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23 (9.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12 (8.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.2%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23 (8.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10 (3.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.4%<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">NYHA class<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">53 (22.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50 (35.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">35.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">133 (46.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">181 (59.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56.9%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">128 (55.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68 (48.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">54.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">109 (38.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">101 (33.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36.0%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27 (11.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12 (8.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24 (8.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12 (4.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.5%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.3%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (3.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5 (1.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2 (0.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died (class &#x02018;5&#x02032;)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17 (7.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9 (6.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14 (4.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6 (2.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.1%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Subsets of LVEF<hr/></td><td colspan="4" valign="top" align="left" rowspan="1">Patients with HFm/pEF<hr/></td><td colspan="4" valign="top" align="left" rowspan="1">Patients with HFrEF<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<hr/>
</td><td colspan="2" valign="top" align="left" rowspan="1">Raw data<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">Weighted data<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">Raw data<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">Weighted data<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">DAPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">EMPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">DAPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">EMPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">DAPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">EMPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">DAPA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">EMPA<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">158<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">215<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">158<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">215<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">359<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">229<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">359<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">229<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died or MACE<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20 (12.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19 (8.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48 (13.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (6.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.1%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.7%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10 (6.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (3.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21 (5.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8 (3.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.3%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MACE<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11 (7.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15 (7.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.3%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">35 (9.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7 (3.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.4%<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">NYHA class<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65 (41.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">115 (53.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47.2%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.2%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">121 (33.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">116 (50.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">35.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.3%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69 (43.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">79 (36.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.3%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">168 (46.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90 (39.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39.8%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10 (6.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11 (5.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.7%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.0%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41 (11.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.6%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.2%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4 (2.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.9%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.5%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8 (2.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.4%<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.4%<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Died (class &#x02018;5&#x02032;)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3.9%</td><td valign="top" align="left" rowspan="1" colspan="1">4.0%</td><td valign="top" align="left" rowspan="1" colspan="1">21 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5.7%</td><td valign="top" align="left" rowspan="1" colspan="1">4.3%</td></tr></tbody></table></table-wrap><fig position="float" id="F4" fig-type="figure"><label>Figure 4</label><caption><p>Summary of the analysis of chronic kidney disease (CKD), and of left ventricular ejection fraction (mildly reduced/preserved [HFm/pEF] or reduced [HFrEF]) as moderators of the dapagliflozin (DAPA) vs empagliflozin (EMPA) differences in the primary (incidence of all-cause mortality/major adverse cardiovascular events, MACE) and secondary (New York Heart Association, NYHA, class at the control visit) outcomes. Effect estimates are for the DAPA vs EMPA contrast: relative risks (RR) for the primary and odds ratios (OR) for the secondary outcomes (pooled data on prevalent and incident patients). Black squares (bars) denote observed effects. Gray squares and diamonds (bars) and font denote estimates corrected for a hypothetical bias disfavoring dapagliflozin or empagliflozin, respectively (see footnote to <xref rid="F3" ref-type="fig">Figure 3</xref> for details).</p></caption><graphic xlink:href="CroatMedJ_66_0135-F4" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The present analysis suggests that patients prescribed with dapagliflozin had a higher risk of a composite of all-cause mortality/incidence or MACE (dominated by HF deterioration) over the initial 6 months of treatment than those prescribed with empagliflozin, and that they were also more likely to present with a worse NYHA class after 6 months of treatment (on the intent-to-treat basis). The estimates were consistent in the two patient subsets (incident and prevalent), justifying pooled analysis to improve precision. Exploratory analysis suggested effect modification: differences between treatments were apparent in patients with preserved renal function (corresponds to eGFR&#x0003e;60 mL/min/1.73 m<sup>2</sup>), and in those with HFrEF but not in patients with CKD or in patients with HFm/pEF. However, patient subsets were limited in size (particularly, the number of patients with CKD and those with HFm/pEF was limited).</p><p>Since contrary to our expectations, the observed estimates prompted us to first consider potential biases. Theoretically (single center, limited sample), the observed findings could have been due to chance. Several elements, however, support a reasonable external validity of the study: i) the general, (co)morbidity and treatment (other than SGLT2i) characteristics of the included patients were in agreement with those reported in pivotal trials of dapagliflozin and empagliflozin in this setting (<xref rid="R12" ref-type="bibr">12</xref>), and in a recent pharmacoepidemiological study (<xref rid="R15" ref-type="bibr">15</xref>); (ii) the primary outcome included all-cause death and MACE, rather than specifically cardiovascular death and hospitalization for HF/or HF-related events typically used in clinical trials in this setting. However, MACE was predominated by &#x0201c;HF worsening events.&#x0201d; Also, all-cause mortality in a real-life setting is likely a more suitable outcome than the cause-specific mortality, since a detailed adjudication is commonly not possible &#x02013; it is less susceptible to misclassification bias and has a direct clinical/practical meaning. It is therefore justified to consider that the primary outcome in the present analysis captures the same trait as does the one used in randomized trials, and it is unlikely that its definition biased the direction of the estimates. The observed overall raw incidence of 10.6% (102 events/961 patients) over 6 months is in line with plausible expectations, considering 6-month occurrence of &#x0201c;primary composites&#x0201d; in a mixed population of HFpEF, HFmrEF, and HFrEF patients in clinical trials (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>); iii) the weighted incidence of the primary outcome in the pooled data (12.5% dapagliflozin vs 8.2% empagliflozin) corresponds to 64 vs 36 events &#x02013; it is unlikely that a few events less or more (by chance) occurring in dapagliflozin or empagliflozin-prescribed patients would have substantially changed the direction of the estimates; iv) the NYHA class outcomes were in the same direction as the primary outcome. We therefore deem it reasonable to view the present data as plausible and reasonably robust, at least considering the entire sample of patients.</p><p>We believe that the present analysis was reasonably well protected against major biases imminent to observational data (<xref rid="R27" ref-type="bibr">27</xref>): i) differential misclassification of outcomes or confounders was unlikely, since all assessments were done in real-time by experienced cardiologists based on objective standard criteria, and irrespective of the present analysis; ii) the only patient selection criteria were a relatively shorter pre-SGLT2i history of heart failure (in prevalent patients), and the absence of some comorbidities typically also excluded in randomized trials. The definition of the NYHA outcome and the intent-to-treat concept minimized the risk of post-baseline selection; iii) in all analyses, dapagliflozin- and empagliflozin -prescribed patients were closely balanced on a wide range of possible confounders. Still, we assumed the existence of residual confounding, potentially arising from a &#x0201c;cumulative effect&#x0201d; of several factors: cumulative minor differences in some of the balanced confounders, differences in dosing/compliance with treatments other than SGLT2i, and other hypothetical sources of confounding. The bias-corrected estimates only mildly differed from the observed ones, and still pointed to poorer outcomes with dapagliflozin. The E-values indicated that whatever the source of residual confounding might have been, its effect would need to be considerable in order to reduce the point-estimates to 1.10. Overall, while the size of the reported estimates might be debatable, their direction seems to be valid. In this respect, the present observations agree with a recent study (<xref rid="R15" ref-type="bibr">15</xref>) based on administrative data that indicated lower risk (by around 10%) of hospitalizations for HF (HHF) and of all-cause death over 12 months in empagliflozin- vs dapagliflozin-prescribed patients. While the present and the reported estimates (<xref rid="R15" ref-type="bibr">15</xref>) should not be quantitatively compared due to methodological differences, they both point to the same direction.</p><p>In their pivotal placebo-controlled trials, the two SGLT2i displayed apparently similar reductions of the risk of HHF/cardiovascular mortality both in patients with HFrEF and in patients with HFm/pEF (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>). The pharmacoepidemiological study by Modzelewski et al (<xref rid="R15" ref-type="bibr">15</xref>) suggested (similar) superiority of empagliflozin vs dapagliflozin in patients with HRrEF, patients with HFm/pEF, and overall (66% with HFrEF). Generally, discrepancies between estimates from quality randomized trials and non-randomized studies can be commonly explained by systematic errors in the latter (<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>), but no such marked biases appear obvious in the reported observational data (<xref rid="R15" ref-type="bibr">15</xref>). We argue that the same applies to the present analysis in the entire patient sample and in patients with HFrEF (60% of all). The presently reported lack of obvious differences between dapagliflozin and empagliflozin in patients with HFm/pEF might not be biased, and agrees with the general messages of the randomized trials, but it is difficult to interpret owing to a very limited number of patients in this subset. The same reasoning is applicable to the observed differences between dapagliflozin and empagliflozin in patients with preserved renal function (60% of all), but not in those with CKD. In the pivotal trials, both in HFrEF and in HFm/pEF (<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R7" ref-type="bibr">7</xref>), the benefits of the two SGLT2i (vs placebo) were similar in patients with eGFR&#x02264;60 mL/min/1.73 m<sup>2</sup> and in patients with preserved renal function. In the study by Modzelewski et al (<xref rid="R15" ref-type="bibr">15</xref>), renal function was not evaluated as a possible effect modifier, but around 70%-75% of the analyzed patients had reasonably preserved renal function (<xref rid="R15" ref-type="bibr">15</xref>). In this context, the present data suggest relative efficacy of the two SGLT2i in patients with CHF conditional on the renal function as a topic that deserves to be investigated.</p><p>Empagliflozin shows a greater selectivity to SGLT2 vs SGLT1 (the latter being expressed also in the heart) than dapagliflozin, and it is tempting to assume that different gliflozins might differ in some &#x0201c;mechanistic&#x0201d; details to the extent that could result in clinically relevant differences (<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>), but at present no such prominent property has been identified. Indirect comparisons generated in network meta-analyses of randomized trials of different gliflozins in different clinical settings (diabetes, CKD, CHF) provide circumstantial evidence to support the hypothesis that cardiovascular outcomes might somewhat differ between different compounds (<xref rid="R30" ref-type="bibr">30</xref>-<xref rid="R32" ref-type="bibr">32</xref>). The present and the published (<xref rid="R15" ref-type="bibr">15</xref>) observational direct comparisons of dapagliflozin to empagliflozin support the hypothesis that the efficacy of the two specifically in CHF might differ to a practically relevant extent &#x02013; a possibility that deserves a proper evaluation.</p><sec><title>Conclusion</title><p>In the present single-center registry analysis, incident or prevalent CHF patients prescribed with dapagliflozin were more likely to experience a composite of all-cause death or MACE over the initial 6 months of treatment than their empagliflozin -prescribed peers, and they were also more likely to display a worse NYHA class at 6 months. While the analysis is limited by a relatively limited single-center patient sample and limited follow-up, it is reasonable to consider it internally valid, and the reported estimates agree with recently reported superiority of empagliflozin vs dapagliflozin in treatment of CHF in a large pharmacoepidemiological study based on claims data (<xref rid="R15" ref-type="bibr">15</xref>). Taken together, the present and the published data (<xref rid="R15" ref-type="bibr">15</xref>) strongly emphasize a need for a direct randomized comparison of empagliflozin and dapagliflozin in CHF patients.</p></sec></sec></body><back><ack><p>Funding None.</p><p>Ethical approval The Ethics Committee at the University Hospital Dubrava (2022/1403-01) confirmed that no ethical approval was required for the analysis of observational data, collected through routine standard procedures.</p><p>Declaration of authorship IJ, IH, HJ, VT conceived and designed the study; IJ, IH, HJ, DR, NP, MR, &#x00160;M acquired the data; IJ, VT analyzed and interpreted the data; IJ, VT drafted the manuscript; all authors critically reviewed the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.</p><p>Competing interests IJ,IH, HJ, NP, &#x00160;M received speaker fees from Boehringer Ingelheim and Astra Zeneca unrelated to the submitted work. VT received consultancy fees from Boehringer Ingelheim Zagreb d.o.o. pertaining to local regulatory topics, but has no competing interests to declare regarding the present work. All authors have completed the Unified Competing Interest form at <ext-link xlink:href="http://www.icmje.org/coi_disclosure.pdf" ext-link-type="uri">www.icmje.org/coi_disclosure.pdf</ext-link> (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McDonagh</surname><given-names>TA</given-names></name>
<name><surname>Metra</surname><given-names>M</given-names></name>
<name><surname>Adamo</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>ESC Scientific document group. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.</article-title>
<source>Eur Heart J</source>
<year>2023</year>
<volume>44</volume>
<fpage>3627</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehad195</pub-id>
<pub-id pub-id-type="pmid">37622666</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zinman</surname><given-names>B</given-names></name>
<name><surname>Wanner</surname><given-names>C</given-names></name>
<name><surname>Lachin</surname><given-names>JM</given-names></name>
<etal/>
</person-group>
<article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.</article-title>
<source>N Engl J Med</source>
<year>2015</year>
<volume>373</volume>
<fpage>2117</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id>
<pub-id pub-id-type="pmid">26378978</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wiviott</surname><given-names>SD</given-names></name>
<name><surname>Raz</surname><given-names>I</given-names></name>
<name><surname>Bonaca</surname><given-names>MP</given-names></name>
<etal/>
</person-group>
<article-title>Dapagliflozin and cardiovascular outcomes in type 2 diabetes.</article-title>
<source>N Engl J Med</source>
<year>2019</year>
<volume>380</volume>
<fpage>347</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1812389</pub-id>
<pub-id pub-id-type="pmid">30415602</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJV</given-names></name>
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>Inzucchi</surname><given-names>SE</given-names></name>
<etal/>
</person-group>
<article-title>Dapagliflozin in patients with heart failure and reduced ejection fraction.</article-title>
<source>N Engl J Med</source>
<year>2019</year>
<volume>381</volume>
<fpage>1995</fpage>
<lpage>2008</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1911303</pub-id>
<pub-id pub-id-type="pmid">31535829</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>McMurray</surname><given-names>JJV</given-names></name>
<name><surname>Claggett</surname><given-names>B</given-names></name>
<etal/>
</person-group>
<article-title>Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.</article-title>
<source>N Engl J Med</source>
<year>2022</year>
<volume>387</volume>
<fpage>1089</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa2206286</pub-id>
<pub-id pub-id-type="pmid">36027570</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Packer</surname><given-names>M</given-names></name>
<name><surname>Anker</surname><given-names>SD</given-names></name>
<name><surname>Butler</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Cardiovascular and renal outcomes with empagliflozin in heart failure.</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<fpage>1413</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa2022190</pub-id>
<pub-id pub-id-type="pmid">32865377</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Anker</surname><given-names>SD</given-names></name>
<name><surname>Butler</surname><given-names>J</given-names></name>
<name><surname>Filippatos</surname><given-names>G</given-names></name>
<etal/>
</person-group>
<article-title>Empagliflozin in heart failure with a preserved ejection fraction.</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>385</volume>
<fpage>1451</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa2107038</pub-id>
<pub-id pub-id-type="pmid">34449189</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>S</given-names></name>
<name><surname>Singh</surname><given-names>T</given-names></name>
<name><surname>Newby</surname><given-names>DE</given-names></name>
<name><surname>Singh</surname><given-names>J</given-names></name>
</person-group>
<article-title>Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.</article-title>
<source>Heart</source>
<year>2021</year>
<volume>107</volume>
<fpage>1032</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1136/heartjnl-2020-318060</pub-id>
<pub-id pub-id-type="pmid">33637556</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Packer</surname><given-names>M</given-names></name>
</person-group>
<article-title>Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis.</article-title>
<source>Circulation</source>
<year>2022</year>
<volume>146</volume>
<fpage>1383</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.061732</pub-id>
<pub-id pub-id-type="pmid">36315602</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Staruschenko</surname><given-names>A</given-names></name>
</person-group>
<article-title>SGLT2 inhibitors: not every drug has the same effect.</article-title>
<source>Am J Physiol Renal Physiol</source>
<year>2024</year>
<volume>326</volume>
<fpage>F1039</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1152/ajprenal.00126.2024</pub-id>
<pub-id pub-id-type="pmid">38695073</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zanad</surname><given-names>F</given-names></name>
<name><surname>Ferreira</surname><given-names>JP</given-names></name>
<name><surname>Pocock</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>
<article-title>SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPAGLIFLOZIN-HF trials.</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>396</volume>
<fpage>819</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31824-9</pub-id>
<pub-id pub-id-type="pmid">32877652</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vaduganathan</surname><given-names>M</given-names></name>
<name><surname>Docherty</surname><given-names>KF</given-names></name>
<name><surname>Claggett</surname><given-names>B</given-names></name>
<etal/>
</person-group>
<article-title>SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials.</article-title>
<source>Lancet</source>
<year>2022</year>
<volume>400</volume>
<fpage>757</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(22)01429-5</pub-id>
<pub-id pub-id-type="pmid">36041474</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nechi</surname><given-names>RN</given-names></name>
<name><surname>Rane</surname><given-names>A</given-names></name>
<name><surname>Karaye</surname><given-names>RM</given-names></name>
<etal/>
</person-group>
<article-title>Cost-effectiveness of dapagliflozin vs empagliflozin for treating heart failure with reduced ejection fraction in the United States.</article-title>
<source>Clin Ther</source>
<year>2023</year>
<volume>45</volume>
<fpage>627</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinthera.2023.05.002</pub-id>
<pub-id pub-id-type="pmid">37270374</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rane</surname><given-names>A</given-names></name>
<name><surname>Nechi</surname><given-names>RN</given-names></name>
<name><surname>Imam</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.</article-title>
<source>J Manag Care Spec Pharm</source>
<year>2023</year>
<volume>29</volume>
<fpage>1045</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.18553/jmcp.2023.29.9.1045</pub-id>
<pub-id pub-id-type="pmid">37610112</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Modzelewski</surname><given-names>KL</given-names></name>
<name><surname>Pipilas</surname><given-names>A</given-names></name>
<name><surname>Bosch</surname><given-names>NA</given-names></name>
</person-group>
<article-title>Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure.</article-title>
<source>JAMA Netw Open</source>
<year>2024</year>
<volume>7</volume>
<elocation-id>e249305</elocation-id>
<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.9305</pub-id>
<pub-id pub-id-type="pmid">38696170</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McDonagh</surname><given-names>T</given-names></name>
<name><surname>Metra</surname><given-names>M</given-names></name>
<name><surname>Adamo</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the Heart failure association (HFA) of the ESC.</article-title>
<source>Eur Heart J</source>
<year>2021</year>
<volume>42</volume>
<fpage>3599</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehab368</pub-id>
<pub-id pub-id-type="pmid">34447992</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="other">Forxiga 5 mg, 10 mg film-coated tablets. Summary of product characteristics. European Medicines Agency 2024. Accessed June 15, 2024 <italic>Forxiga, INN-dapagliflozin (europa.eu)</italic>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="other">Jardiance 10 mg, 25 mg film-coated tablets. Summary of product characteristics. European Medicines Agency 2024. Accessed June 15, 2024. <italic>Jardiance, INN-Empagliflozin (europa.eu)</italic>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zubizarreta</surname><given-names>JR</given-names></name>
</person-group>
<article-title>Stable weights that balance covariates for estimation with incomplete outcome data.</article-title>
<source>J Am Stat Assoc</source>
<year>2015</year>
<volume>110</volume>
<fpage>910</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1080/01621459.2015.1023805</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="webpage">Greifer N. optweight: Targeted Stable Balancing Weights Using Optimization. R package version 0.2.5.9001, 2024, <ext-link xlink:href="https://github.com/ngreifer/optweight" ext-link-type="uri">https://github.com/ngreifer/optweight</ext-link><italic>.</italic></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="webpage">R Core Team. R: a language and environment fo statistical computing. R Foundation for statistical computing, Vienna, Austria. 2021. <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ratitch</surname><given-names>B</given-names></name>
<name><surname>Bell</surname><given-names>J</given-names></name>
<name><surname>Mallinckrodt</surname><given-names>C</given-names></name>
<etal/>
</person-group>
<article-title>Choosing estimands in clinical trials: putting the ICH E9(R1) into perspective.</article-title>
<source>Ther Innov Regul Sci</source>
<year>2020</year>
<volume>54</volume>
<fpage>324</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1007/s43441-019-00061-x</pub-id>
<pub-id pub-id-type="pmid">32072573</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>B&#x000fc;rkner</surname><given-names>PC</given-names></name>
</person-group>
<article-title>Brms: An R package for Bayesian multilevel models using Stan.</article-title>
<source>J Stat Softw</source>
<year>2017</year>
<volume>80</volume>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.18637/jss.v080.i01</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schneewiess</surname><given-names>S</given-names></name>
</person-group>
<article-title>Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.</article-title>
<source>Pharmacoepidemiol Drug Saf</source>
<year>2006</year>
<volume>15</volume>
<fpage>291</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1002/pds.1200</pub-id>
<pub-id pub-id-type="pmid">16447304</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="webpage">Haine D. The episensr package: basic sensitivity analysis of epidemiological results. 2023, R package version 1.3.0, <ext-link xlink:href="https://dhaine.github.io/episensr/" ext-link-type="uri">https://dhaine.github.io/episensr/</ext-link>.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>VanderWeele</surname><given-names>TJ</given-names></name>
<name><surname>Ding</surname><given-names>P</given-names></name>
</person-group>
<article-title>Sensitivity analysis in observational research: introducing the E-value.</article-title>
<source>Ann Intern Med</source>
<year>2017</year>
<volume>167</volume>
<fpage>268</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.7326/M16-2607</pub-id>
<pub-id pub-id-type="pmid">28693043</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="book">Rothman KJ, Greenland S, Lash TL. Validity in epidemiological studies. In: Rothman KJ, Greenland S, Lash TL. (Eds.), Modern epidemiology 3rd edition, Lippincott Williams&#x00026; Wilkins, Philadepphia, USA. 2008, pp 128-146.</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mathes</surname><given-names>T</given-names></name>
<name><surname>Rombey</surname><given-names>T</given-names></name>
<name><surname>Kuss</surname><given-names>O</given-names></name>
<name><surname>Pieper</surname><given-names>D</given-names></name>
</person-group>
<article-title>No inexplicable disagreement between real-world data-based nonrandomized controlled studies and randomized trials were found.</article-title>
<source>J Clin Epidemiol</source>
<year>2021</year>
<volume>133</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.12.019</pub-id>
<pub-id pub-id-type="pmid">33359322</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Toews</surname><given-names>I</given-names></name>
<name><surname>Anglemyer</surname><given-names>A</given-names></name>
<name><surname>Nyirenda</surname><given-names>JLZ</given-names></name>
<etal/>
</person-group>
<article-title>Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study.</article-title>
<source>Cochrane Database Syst Rev</source>
<year>2024</year>
<volume>1</volume>
<elocation-id>MR000034</elocation-id>
<pub-id pub-id-type="pmid">38174786</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kongmalai</surname><given-names>T</given-names></name>
<name><surname>Nadnorntun</surname><given-names>P</given-names></name>
<name><surname>Leelahavarong</surname><given-names>P</given-names></name>
<etal/>
</person-group>
<article-title>Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.</article-title>
<source>Front Endocrinol</source>
<year>2023</year>
<volume>14</volume>
<elocation-id>1216160</elocation-id>
<pub-id pub-id-type="doi">10.3389/fendo.2023.1216160</pub-id>
<pub-id pub-id-type="pmid">38179304</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tager</surname><given-names>T</given-names></name>
<name><surname>Atar</surname><given-names>D</given-names></name>
<name><surname>Agewall</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomesi n type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trial.</article-title>
<source>Heart Fail Rev</source>
<year>2021</year>
<volume>26</volume>
<fpage>1421</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1007/s10741-020-09954-8</pub-id>
<pub-id pub-id-type="pmid">32314085</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Goshal</surname><given-names>S</given-names></name>
<name><surname>Sinha</surname><given-names>B</given-names></name>
</person-group>
<article-title>Exploring the comparative cardiovasculare death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.</article-title>
<source>Front Endocrinol</source>
<year>2023</year>
<volume>14</volume>
<elocation-id>1168755</elocation-id>
<pub-id pub-id-type="doi">10.3389/fendo.2023.1168755</pub-id>
</mixed-citation></ref></ref-list><sec sec-type="supplementary-material"><title>Additional Material</title><supplementary-material id="S16" position="float" content-type="local-data"><caption><title>Supplemental Material 1</title></caption><media xlink:href="CroatMedJ_66_s016.pdf" id="d67e6820" position="anchor"/></supplementary-material><supplementary-material id="S17" position="float" content-type="local-data"><caption><title>Supplemental Material 2</title></caption><media xlink:href="CroatMedJ_66_s017.pdf" id="d67e6824" position="anchor"/></supplementary-material></sec></back></article>